Sanofi Shares Outstanding vs. Revenue
| SNYN Stock | MXN 991.38 27.38 2.84% |
For Sanofi profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sanofi to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sanofi utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sanofi's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sanofi over time as well as its relative position and ranking within its peers.
Sanofi |
Sanofi Revenue vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sanofi's current stock value. Our valuation model uses many indicators to compare Sanofi value to that of its competitors to determine the firm's financial worth. Sanofi is rated third in shares outstanding category among its peers. It is rated fourth in revenue category among its peers totaling about 18.35 of Revenue per Shares Outstanding. Comparative valuation analysis is a catch-all model that can be used if you cannot value Sanofi by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sanofi's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sanofi Revenue vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Sanofi |
| = | 2.47 B |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Sanofi |
| = | 45.39 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Sanofi Revenue vs Competition
Sanofi is rated fourth in revenue category among its peers. Market size based on revenue of Drug Manufacturers - Major industry is at this time estimated at about 305.99 Billion. Sanofi retains roughly 45.39 Billion in revenue claiming about 15% of equities under Drug Manufacturers - Major industry.
Sanofi Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sanofi, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sanofi will eventually generate negative long term returns. The profitability progress is the general direction of Sanofi's change in net profit over the period of time. It can combine multiple indicators of Sanofi, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1 and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. SANOFI is traded on Mexico Stock Exchange in Mexico.
Sanofi Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sanofi. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sanofi position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sanofi's important profitability drivers and their relationship over time.
Use Sanofi in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sanofi position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sanofi will appreciate offsetting losses from the drop in the long position's value.Sanofi Pair Trading
Sanofi Pair Trading Analysis
The ability to find closely correlated positions to Sanofi could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sanofi when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sanofi - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sanofi to buy it.
The correlation of Sanofi is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sanofi moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sanofi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sanofi can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sanofi position
In addition to having Sanofi in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Sanofi Stock Analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.